First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors

information fournie par Boursorama •17/10/2018 à 18:00

TG6002 Has Multiple Mechanisms of Action for Enhanced Anti-Tumor Activity: Oncolysis, Local Production of Chemotherapy in Tumor and Cell-Mediated Immune Response

Strasbourg, France, October 17, 2018, 6:00 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, today announced that the first patient of a Phase 1/2 clinical trial evaluating TG6002 in patients with advanced gastrointestinal tumors, such as colon cancers, has been dosed at Centre Léon Bérard (France). This multicenter trial has already been approved in France, Belgium and Spain and will enroll up to 59 patients.

TG6002 is a next-generation oncolytic virus (OV), which can be administered intravenously and has multiple mechanisms of action. It has been engineered to combine the killing of cancer cells (oncolysis), the production of 5-FU, a widely used chemotherapy agent, in the tumor site, and the induction of immunogenic cell death by eliciting an immune response against tumor cells. TG6002 expresses the proprietary FCU1 gene in the cancer cells it has infected, leading to local conversion of the pro-drug 5-FC (administered orally) into 5-FU. This is particularly important as most gastrointestinal tumors are 5-FU sensitive.
.../...